Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

174.57 +1.95 (+1.13%)

Streaming Delayed Price Updated: 11:23 AM EST, Jan 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9

...

57 58 Next >

Explore the top gainers and losers within the S&P500 index in today's session. ↗

November 13, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.

Via Chartmill

5 Insightful Analyst Questions From Biogen’s Q3 Earnings Call

November 06, 2025

Biogen’s third quarter results came in ahead of Wall Street’s revenue and profit expectations, driven by robust performance from recently launched products and continued strength in its multiple...

Via StockStory

Topics Earnings

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

November 03, 2025

From Biogen Inc.

Via GlobeNewswire

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal ↗

October 24, 2025

Via Stocktwits

BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands

October 31, 2025

Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q3 CY2025, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above...

Via StockStory

Biogen (NASDAQ:BIIB) Beats Q3 Sales Expectations

October 30, 2025

Biotech company Biogen (NASDAQ:BIIB) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was...

Via StockStory

Topics Artificial Intelligence

Biogen Sinks Back Into A Buy Zone After Cutting Its Profit Guide ↗

October 30, 2025

Biogen stock fell early Thursday after the biotech company cut its 2025 profit outlook due to an expected tax charge.

Via Investor's Business Daily

Examining the Future: Biogen's Earnings Outlook ↗

October 29, 2025

Via Benzinga

Biogen (BIIB) Reports Earnings Tomorrow: What To Expect

October 28, 2025

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results this Thursday before market open. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

Biogen's Immunology Pipeline Has Long-Term Potential: Analyst ↗

October 24, 2025

Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across multiple immune diseases.

Via Benzinga

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

October 24, 2025

From Biogen Inc.

Via GlobeNewswire

3 Profitable Stocks We Steer Clear Of

October 24, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

October 22, 2025

From Biogen Inc.

Via GlobeNewswire

ARPA-H Taps Former DARPA Innovator to Ignite High-Risk, High-Reward Health Tech Revolution

October 21, 2025

In a move poised to reshape the landscape of biomedical innovation, the United States government officially appointed Dr. Renee Wegrzyn, a distinguished former official from the Defense Advanced...

Via TokenRing AI

Topics Artificial Intelligence Intellectual Property

J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround ↗

October 19, 2025

Via The Motley Fool

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗

October 16, 2025

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.

Via Benzinga

3 Reasons BIIB is Risky and 1 Stock to Buy Instead

October 16, 2025

Biogen has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 26.6% to $146 per share while the index has gained 26.5%.

Via StockStory

Topics Government Stocks World Trade

1 Healthcare Stock to Research Further and 2 We Find Risky

October 14, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,...

Via StockStory

Topics Stocks

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

October 13, 2025

From Biogen Inc.

Via GlobeNewswire

Reflecting On Therapeutics Stocks’ Q2 Earnings: Amgen (NASDAQ:AMGN)

October 12, 2025

Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers.

Via StockStory

Topics Artificial Intelligence

UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know

October 10, 2025

A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.

Via StockStory

Topics Economy Government World Trade

7 Analysts Have This To Say About Biogen ↗

October 10, 2025

Via Benzinga

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

October 09, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

October 09, 2025

From Biogen Inc.

Via GlobeNewswire

1 Value Stock with Promising Prospects and 2 We Avoid

October 09, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

Via StockStory

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...

Via MarketMinute

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease

October 06, 2025

From Biogen Inc.

Via GlobeNewswire

Which S&P500 stocks are moving on Monday? ↗

October 06, 2025

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Monday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Nasdaq 100 Top 25,000 As AMD Spikes, Gold Eyes $4,000: What's Moving Markets Monday? ↗

October 06, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.